Trials / Completed
CompletedNCT05546151
A Study to Assess the Safety and Tolerability of BMS-986322 in Healthy Participants of Japanese Descent
A Double-blind, Placebo-controlled, Randomized, Multiple Ascending Dose Study of the Safety, Tolerability, and Pharmacokinetics of BMS-986322 in Healthy Participants of Japanese Descent
- Status
- Completed
- Phase
- Phase 1
- Study type
- Interventional
- Enrollment
- 24 (actual)
- Sponsor
- Bristol-Myers Squibb · Industry
- Sex
- All
- Age
- 18 Years – 60 Years
- Healthy volunteers
- Accepted
Summary
The purpose of this study is to assess the safety and tolerability of multiple ascending oral doses of BMS-986322 in healthy participants of Japanese descent.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | BMS-986322 | Specified dose on specified days |
| OTHER | Placebo for BMS-986322 | Specified dose on specified days |
Timeline
- Start date
- 2022-09-28
- Primary completion
- 2023-04-07
- Completion
- 2023-04-07
- First posted
- 2022-09-19
- Last updated
- 2023-06-22
Locations
1 site across 1 country: United States
Regulatory
- FDA-regulated drug study
Source: ClinicalTrials.gov record NCT05546151. Inclusion in this directory is not an endorsement.